MK-677 vs Vesilute
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% MK-677 and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
MK-677 Vesilute
Weight 624.77 Da 262 Da
Half-life ~24 hours Not established
Chain — 2 amino acids
Type Non-peptide ghrelin receptor agonist Dipeptide bioregulator
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Research Evidence
MK-677 Vesilute
Status Well Studied Moderate Research
References 7 studies 3 studies
Latest July 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.